Enzyme-Inducing Medications That Reduce Anti-Seizure Drug Effectiveness
Phenobarbital, phenytoin, and carbamazepine are the primary culprits that induce hepatic enzymes and reduce the effectiveness of other anti-seizure medications and numerous co-administered drugs through stimulation of cytochrome P450 and glucuronyl transferase enzyme systems 1, 2.
Primary Enzyme-Inducing Anti-Seizure Medications
The following ASDs are potent hepatic enzyme inducers that will decrease plasma concentrations of co-administered medications:
- Carbamazepine
- Phenytoin
- Phenobarbital
- Primidone (metabolized partly to phenobarbital)
These agents induce both monooxygenase and conjugating enzymes, accelerating the metabolism of lipid-soluble drugs and attenuating their pharmacological effects 1, 3.
Affected Drug Classes
When enzyme-inducing ASDs are prescribed, they reduce the effectiveness of:
Other Anti-Seizure Medications
Non-Neurological Medications
- Oral contraceptives - leading to contraceptive failure risk 1, 2
- Anticoagulants (warfarin) - requiring dose adjustments 1, 4
- Immunosuppressants (cyclosporin A) - risking transplant rejection 1, 2
- Cardiovascular drugs - including antihypertensives 1, 2
- Cytotoxic/antineoplastic agents (taxanes, vinca alkaloids, methotrexate, teniposide, camptothecin analogues) - causing insufficient tumor control 5
- Antiretrovirals - potentially leading to progressive AIDS 1
- Glucocorticoids 1, 4
- Statins 1
- Psychotropic drugs 2
- Analgesics 1
Clinical Consequences
The enzyme induction process creates serious clinical risks:
- Higher cancer mortality due to reduced chemotherapy effectiveness 1
- Transplant rejection from subtherapeutic immunosuppressant levels 1
- Unwanted pregnancy from oral contraceptive failure 1, 2
- Progressive AIDS from inadequate antiretroviral levels 1
- Endogenous metabolic disruption affecting bone biochemistry, gonadal steroids, and lipid markers, potentially contributing to osteoporosis, sexual dysfunction, and vascular disease 1
Critical Withdrawal Consideration
When discontinuing enzyme-inducing ASDs, the concentrations of co-administered drugs will increase substantially, bringing significant risk of toxicity if doses are not concomitantly reduced 1. This bidirectional risk—both with initiation and withdrawal—remains largely underappreciated in clinical practice.
Safer Alternatives
Modern ASDs without significant enzyme-inducing properties include:
- Levetiracetam - no clinically relevant pharmacokinetic interactions 2
- Gabapentin - no clinically relevant pharmacokinetic interactions 2
- Pregabalin - no clinically relevant pharmacokinetic interactions 2
Given that non-enzyme-inducing ASDs have similar efficacy for common epilepsies, strong consideration should be given to starting treatment with these agents rather than enzyme-inducing ASDs 1.
Moderate Enzyme Inducers
Oxcarbazepine has weaker enzyme-inducing effects but can still stimulate metabolism of oral contraceptive steroids at therapeutic doses 2. Lamotrigine, felbamate, and topiramate (at high doses) may also affect oral contraceptive metabolism 2.
Non-Inducing ASD with Inhibitory Effects
Valproic acid does not induce enzymes but inhibits metabolism of select substrates, most notably phenobarbital and lamotrigine, potentially causing toxicity of these agents 2, 3.